Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic treatment of hemiplegic migraine with lamotrigine
2016-003223-30Phase 3Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lamotrigine in familial hemiplegic migraine (FHM), sponsored by University Hospital Tübingen. Primary endpoint: Change in number of hemiplegic migraine attacks. Started Feb 2017; status: terminated.
02
Drugs
lamotrigine
03
Conditions
familial hemiplegic migraine (FHM)
Beyond the preview
Go deeper on 2016-003223-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003223-30.